

# T cell development and tolerance

Mark S. Anderson  
Diabetes Center  
UCSF



University of California  
San Francisco

*advancing health worldwide™*

**FOCiS**





**FOCiS**<sup>®</sup>

ANNUAL MEETING


**BOSTON-2023**

JUNE 20-23

# Lecture outline

- **Central and peripheral tolerance**
- **Inhibitory receptors of T cells**
- **Regulatory T cells**

# The immunological equilibrium: balancing lymphocyte activation and control



# Immunological tolerance

- **Definition:**
  - unresponsiveness to an antigen induced by exposure of lymphocytes to that antigen; antigen-specific (unlike "immunosuppression")
- **Significance:**
  - All individuals are tolerant of their own antigens (**self-tolerance**); breakdown of self-tolerance results in autoimmunity
  - Preventing immune responses to commensal microbes, fetal antigens
  - **Therapeutic potential:** Inducing tolerance may be exploited to treat autoimmune and allergic diseases


## THE PHENOMENON OF TOLERANCE:

Seminal observations in 1945 by **R.D. Owen** that cattle dizygotic twins display red cell (chimerism/mosaicism) in adult life.

Owen interpreted that placenta of cattle dizygotic twins undergo anastomosis early in fetal life permitted blood cells and their precursors to move from one twin to the other.

Tolerance is acquired.

eg. Dizygotic twins in cattle:



**Fig. 2: Dizygotic twins in cattle.**

## **THE PHENOMENON OF TOLERANCE:**

Seminal observations in 1945 by **R.D. Owen** that cattle dizygotic twins display red cell (chimerism/mosaicism) in adult life.

Owen interpreted that placenta of cattle dizygotic twins undergo anastomosis early in fetal life permitted blood cells and their precursors to move from one twin to the other.


**In 1953, BILLINGHAM, BRENT, and MEDAWAR** demonstrated that immunological tolerance could be acquired by introduction of donor cells during fetal development - tolerance permanent and Ag specific




Neonate

Adult


Rejection



+




-



+

# Central and peripheral tolerance to self





*The principal fate of lymphocytes that recognize self antigens in the generative organs is death (deletion)*

*Some B cells may change their specificity (called "receptor editing")*

*Some T cells may differentiate into regulatory (suppressor) T lymphocytes*


# T cell tolerance: Diversity is a challenge





**Thymus**


*Squish to  
release  
cells*



*Coat with  
red-anti-  
CD4  
and  
green anti-  
CD8*

*Analyze using the flow  
cytometer (aka the FACS)*

↑  
CD4




**12% of the cells fall  
in this quadrant  
(these are CD4+CD8-)**

**2.34% of the cells fall  
in this quadrant  
(these are CD4-CD8+)**

Most mature cells (CD4+CD8- or CD4-CD8+)




- called "single positive" because they express either CD4 or



Intermediate cells  
(CD4+CD8+)  
- called "double positive" (DP)  
because they express  
both CD4 and CD8 cells  
[these are the most  
numerous cells in the thymus]

Most immature cells  
(CD4-CD8-)

called "double negative" (DN) because they express neither CD4 nor



# T cell development in the thymus





Figure 7-14 Immunobiology, 6/e. (© Garland Science 2005)

# Consequences of self antigen recognition in thymus






## What self antigens are seen in the thymus?

- Ubiquitous cell-associated and circulating proteins
- The thymus has a special mechanism for displaying peripheral tissue antigens in thymic medullary epithelial cells, where they signal self-reactive thymocytes for death

# Consequences of AIRE mutation


- Human disease: autoimmune polyendocrinopathy with candidiasis and ectodermal dysplasia (APECED), also called autoimmune polyendocrine syndrome (APS-1)
  - Associated gene identified by positional cloning, named *AIRE* ("autoimmune regulator")
- Mouse knockout: autoantibodies against multiple endocrine organs, retina
  - Failure to express many self antigens in the thymus --> failure of negative selection

# Deletion of self-reactive T cells in the thymus: how are self antigens expressed in the thymus?




*AIRE (autoimmune regulator) is a regulator of gene transcription that stimulates thymic expression of many self antigens which are largely restricted to peripheral tissues*


# Peripheral tolerance



# Peripheral T cell tolerance



# T cell anergy




# Inhibitory receptors of T cells

- Prevent reactions against self antigens (their physiologic function)
  - Deletion or blockade of these receptors results in autoimmune diseases
- Suppress immune responses to some tumors, chronic infections (HCV, HIV)
  - Therapeutic application: checkpoint blockade for cancer immunotherapy

# T cell activating and inhibitory receptors


## Inhibitory receptors

## Activating receptors (costimulators)





# Regulatory T cells



# Properties of regulatory T cells

- **Phenotype:** CD4+, high IL-2 receptor (CD25), Foxp3 transcription factor; other markers
- **How do we define Tregs:**
  - In vitro suppression assays
  - In vivo suppression assays (mice)
  - **Cells that prevent autoimmunity**

# The significance of Foxp3+ Tregs

- **Genetic evidence:** Foxp3 mutations --> autoimmune disease (IPEX); in mice, disease can be corrected by providing normal Foxp3+ cells
- Do defects in Foxp3+ Tregs or resistance to Treg-mediated suppression contribute to common autoimmune diseases?
  - Inconsistent and variable data
  - Treg assays are not standardized

# Populations of Tregs

- **Thymic, tTreg ("natural")**
  - Induced by self antigen recognition during T cell maturation
- **Peripheral, pTreg ("adaptive")**
  - In response to antigen exposure in the periphery; contribution to preventing inflammatory disease?
- **In vitro induced, iTreg (sometimes called Tr1)**
  - Culture with  $\text{TGF}\beta$  + IL-2; therapeutic options
- There may not be reliable markers for distinguishing these Tregs in a "bulk" population

# Mechanisms of action of Foxp3+ Tregs

- CTLA-4 on Tregs removes B7 on APCs, reduces CD28 engagement and T cell activation
  - Genetic deletion of CTLA-4 in Foxp3+ cells results in severe systemic autoimmunity and lymphoproliferation
  - Commonly used assay for Treg function in humans bypasses the need for B7 and cannot measure this activity

# Mechanisms of action of Foxp3+ Tregs

- CTLA-4 on Tregs removes B7 on APCs, reduces CD28 engagement and T cell activation
- Inhibitory cytokines produced by Tregs (IL-10, others?) suppress immune responses (DCs, Macs, T cells)
  - IL-10 is especially important for regulating mucosal immune responses (deletion of IL10 in Foxp3+ cells results in colitis)

# Mechanisms of action of Foxp3+ Tregs

- CTLA-4 on Tregs removes B7 on APCs, reduces CD28 engagement and T cell activation
- Inhibitory cytokines produced by Tregs (IL-10, others?) suppress immune responses (DCs, Macs, T cells)
- **Consumption of IL-2**
  - Deletion of IL-2R  $\alpha$  or  $\beta$  chain in Foxp3+ cells causes autoimmunity
- **Many others reported**

# Regulatory T cells


- Explosion of information about the generation, properties, functions and significance of these cells
- Will cellular therapy with ex vivo expanded Treg become a reality?
- **Therapeutic goal:** induction or activation of Treg in immune diseases



# The therapeutic potential of regulatory T lymphocytes

- Cell transfer of autologous Tregs to suppress immune responses
  - Grow up patient's Tregs ex vivo
  - Ongoing clinical trials in graft rejection, T1D show it is safe
  - Very little efficacy data
  - Technically difficult, individualized
  - Heavy new investment: >\$1 Billion invested in Treg companies in last few years


# Chimeric Antigen Receptor (CAR) for Treg's



# The therapeutic potential of regulatory T lymphocytes


- Cell transfer of autologous Tregs to suppress immune responses
- Administer antigen or cytokine in ways that preferentially induce Tregs?
  - IL-2

# Functions of Interleukin-2: the dogma




# Dual roles of IL-2 in T cell responses

## Induction of immune response



## Control of immune response



*Surprising conclusion from knockout mice and patients: the non-redundant function of IL-2 is in controlling immune responses*

# Sensitivity of conventional (responding) and regulatory T cells to IL-2

- Tregs are more sensitive to IL-2 because -
  1. Tregs express higher levels of CD25 and therefore the high-affinity IL-2 receptor
  2. Tregs have a larger intracellular pool of IL-2R chains and can replenish the receptor following ligand-induced internalization
  3. Tregs maintain higher levels of the IL-2-induced transcription factor p-STAT5 and for longer periods

# The role of IL-2 in the lives of regulatory T cells


- **IL-2 is a survival factor for maintaining Tregs in the periphery**
  - Source of IL-2 is T cells that respond to antigens (microbes, other environmental antigens?)
- **IL-2 is also required for the functional competence of Tregs**
  - Promotes FoxP3<sup>+</sup> CTLA-4<sup>+</sup> T cells

# IL-2 dependent activation of regulatory T cells suppresses effector responses

Antigen  
recognition

IL-2 secretion  
by T effs

Activation  
of Tregs



antigen

IL-2

*Tregs do not make their own IL-2*



## Therapeutic potential of IL-2: a revision

- IL-2 was originally used to boost immune responses in cancer, HIV infection (enhancing effector and memory T cells)
  - IL-2 treatment can increase number and functional activity of Tregs
- Use of IL-2 to boost Tregs: design IL-2 to bind to high-affinity CD25
  - Low-dose IL-2
  - Mutant IL-2 that binds preferentially to CD25

## Role of dendritic cells in self-tolerance

- **Mature DCs** (activated during innate immune responses to PAMPs and DAMPs) express costimulators, secrete cytokines, and initiate immune responses
- **Immature (“resting”) DCs** live in tissues, display self antigens and maintain tolerance (by inducing anergy, deletion, and/or Tregs)

# The potential of “tolerogenic antigen-presenting cells”

- Exploiting antigen-pulsed DCs to induce tolerance
  - Phase 1 trial of DCs pulsed with citrullinated peptides in RA published in 2015
  - Maintaining DCs in tolerogenic state?
- Can DCs be modified to make them tolerogenic?
  - Expression of costimulator antagonists, immunosuppressive cytokines, other inhibitors: being tried in animal models of graft rejection

# Strategies for inducing tolerance

- Administration of antigen in tolerogenic form
  - Repeated doses of peptides without adjuvants
  - Only approach for antigen-specific tolerance
  - Understanding mechanism requires assays for antigen-specific lymphocytes
- Triggering inhibitory receptors
  - Risky, difficult to make antibodies that activate and not block receptors
- Treg targeted therapies:
  - Treg cell transfer
  - IL-2

# Regulating immune responses: where are we?

- Elucidating the mechanisms of immune regulation is one of the dominant themes of modern Immunology; obvious relevance to immune-mediated inflammatory diseases, therapeutics, vaccines
- Already leading to new therapeutic strategies
- Continuing challenge is to determine which mechanisms of tolerance fail in different autoimmune diseases